A Phase 1 Study of ABT-767 in BRCA1 or BRCA2 Mutation Carriers With Advanced Solid Tumours and in Subjects With High Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer. This evidence concerns the gene BRCA1 and primary peritoneal carcinoma.